EyePoint, Inc. (FRA:PV3B)

Germany · Delayed Price · Currency is EUR

10.40

-0.20 (-1.89%)

Last updated: Jul 28, 2026, 9:55 AM CET

19.90% (1Y)

Market Cap	914.68M +48.9%
Revenue (ttm)	6.60M -86.4%
Net Income	-235.56M
EPS	-3.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	10.30
Previous Close	10.60
Day's Range	10.30 - 10.40
52-Week Range	8.16 - 15.32
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 31, 2026

About EyePoint

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2000

Employees 214

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol PV3B

Financial Performance

In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.

Financial numbers in USD Financial Statements

News

EyePoint price target lowered to $30 from $33 at JPMorgan

JPMorgan lowered the firm’s price target on EyePoint (EYPT) to $30 from $33 and keeps an Overweight rating on the shares. The firm views the stock’s 30% drop year-to-date as…

6 days ago - TheFly

EyePoint to pay $4.6M to resolve False Claim Act allegations

In a posting on the U.S. Department of Justice’s Office of Public Affairs site, the agency said Eyepoint (EYPT) Pharmaceuticals has agreed to pay the United States 4,657,463.18 to resolve…

11 days ago - TheFly

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

12 days ago - GlobeNewsWire

EyePoint initiated with a Buy at Stifel

Stifel analyst Annabel Samimy initiated coverage of EyePoint (EYPT) with a Buy rating and $40 price target EyePoint’s Duravyu, which provides more complete inhibition of angiogenesis with added potent...

12 days ago - TheFly

EyePoint appoints Tarek Hassan as chief strategic science officer

EyePoint (EYPT) announced the appointment of Tarek Hassan as senior VP, chief strategic science officer. Hassan will report directly to Jay Duker, president and CEO of EyePoint, and will serve…

15 days ago - TheFly

EyePoint Appoints Tarek S. Hassan, M.D.

Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist an...

15 days ago - GlobeNewsWire

EyePoint assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of EyePoint (EYPT) with an Overweight rating and $47 price target ahead of Phase 3 data in neovascular AMD. The Phase 3 LUGANO trial is expected…

20 days ago - TheFly

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities' top picks for the month.

HOOD EHC ERAS MU ORCL

26 days ago - Barrons

EyePoint price target raised to $65 from $29 at Chardan

Chardan analyst Andreas Argyrides raised the firm’s price target on EyePoint (EYPT) to $65 from $29 and keeps a Buy rating on the shares as coverage was transferred. The firm,…

27 days ago - TheFly

EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

DURAVYU, a sustained-release retinal therapy, is advancing through phase III trials for wet AMD and DME, with key data readouts expected soon. The product offers both anti-VEGF and anti-inflammatory effects, strong safety, and commercial readiness, supported by a robust financial runway.

6 weeks ago - Transcripts

EyePoint Transcript: Jefferies Global Healthcare Conference 2026

DURAVYU is advancing through four phase III trials for wet AMD and DME, with key readouts expected in 2024. The therapy aims for non-inferiority in visual acuity, strong safety, and meaningful reduction in treatment burden, while offering a novel mechanism and commercial advantages.

7 weeks ago - Transcripts

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

Phase III trials for DURAVYU in wet AMD and DME are progressing, with key readouts expected in August and late 2027. The drug aims for six-month dosing, offers a differentiated mechanism, and is supported by strong safety and efficacy data. Commercial launch preparations and financial runway extend into 2027.

2 months ago - Transcripts

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se...

2 months ago - GlobeNewsWire

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials

EyePoint (EYPT) announced the independent data safety monitoring committee completed its third scheduled review of the company’s pivotal Phase 3 program evaluating Duravyu for wet age-related macular ...

2 months ago - TheFly

EyePoint's late-stage eye drug trials to continue after safety panel review

EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug ‌Duravyu and recommended the studies continue unchanged.

2 months ago - Reuters

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously...